Bassal, Mahmoud A. http://orcid.org/0000-0003-4322-2968
Samaraweera, Saumya E. http://orcid.org/0000-0002-9619-0624
Lim, Kelly http://orcid.org/0000-0003-4606-7588
Benard, Brooks A. http://orcid.org/0000-0001-7154-744X
Bailey, Sheree http://orcid.org/0000-0001-6690-5476
Kaur, Satinder
Leo, Paul
Toubia, John http://orcid.org/0000-0002-5135-6504
Thompson-Peach, Chloe http://orcid.org/0000-0001-7172-3183
Nguyen, Tran
Maung, Kyaw Ze Ya
Casolari, Debora A. http://orcid.org/0000-0001-5072-0880
Iarossi, Diana G.
Pagani, Ilaria S.
Powell, Jason
Pitson, Stuart http://orcid.org/0000-0002-9527-2740
Natera, Siria
Roessner, Ute http://orcid.org/0000-0002-6482-2615
Lewis, Ian D.
Brown, Anna L. http://orcid.org/0000-0002-9023-0138
Tenen, Daniel G.
Robinson, Nirmal http://orcid.org/0000-0002-7361-9491
Ross, David M.
Majeti, Ravindra http://orcid.org/0000-0002-5814-0984
Gonda, Thomas J.
Thomas, Daniel http://orcid.org/0000-0002-0837-1231
D’Andrea, Richard J. http://orcid.org/0000-0002-4915-4612
Article History
Received: 11 October 2021
Accepted: 20 April 2022
First Online: 12 May 2022
Change Date: 15 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-31952-7
Competing interests
: R.M. is on the Board of Directors of CircBio Inc., and Advisory Boards of Kodikaz Therapeutic Solutions Inc. and Syros Pharmaceuticals. R.M. is an equity holder and founder of CircBio Inc. and Pheast Therapeutics Inc.. R.M. is an inventor on several patents related to CD47 cancer immunotherapy licensed to Gilead Sciences, Inc. that are not directly related to the research in this study. The remaining authors declare no competing interests.